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mmHg for liraglutide versus 130.1 (130.0, 130.1)/75.4 (75.4, 75.5) mmHg and 130.1
(129.0, 131.2)/75.5 (74.8, 76.1) mmHg for all comparison patients and per bootstrap,
respectively (p0.05 except bootstrap diastolic BP p0.05). CONCLUSIONS: A boot-
strap analysis provided more robust variance and 95% CI estimates for a large
comparison group. This technique can help researchers avoid identifying statisti-
cal significance when differences are not clinically meaningful when evaluating a
large patient cohort.
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EVOLVING CONCEPTS IN OUTCOMES RESEARCH
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DEVELOPMENT OF A GUIDANCE FOR INCLUDING PATIENT-REPORTED
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OBJECTIVES:Although an FDAGuidance is available to direct the development and
inclusion of PROs in preapproval clinical research towards drug approval and la-
beling, no such guidance exists in the post-market CER context. Because the clin-
ical setting and stakeholders in CER differ from the preapproval space, different
methodological and practical considerations are necessary. The aim of this project
is to develop specific recommendations for capturing the patient perspective in
post-market oncology trials and other studies that fall into the general category
termed CER. METHODS: A semi-structured questionnaire pertaining to the use of
PROs in CER was developed based on a review of scientific literature and consulta-
tion with PRO study methodologists. In-depth interviews were conducted using
these questions with 15 individuals from the clinical research, clinical practice,
regulatory, payer, and patient communities. Based on interview responses, a list of
potential guidance topicswas developed. The Center forMedical Technology Policy
convened a multidisciplinary working group of leading medical researchers in
PROs, ePRO consultants, and patient advocates to discuss these topics and develop
an on outline of best practice recommendations for integrating PROs in CER.
RESULTS: A series of recommendations focused on establishing standards for the
use of PROs in CER were developed. These recommendations address selection of
appropriate measures; inclusion of a ”core minimum item set” across all oncology
CER trials; and inclusion of items which assess symptoms, global QOL, perceived
value of care, and treatment compliance. The recommendations also provide guid-
ance for how to implement PROs in real-world studies andminimize missing data.
CONCLUSIONS: The patient perspective is an essential component of CER. PRO
methods used in CER differ from the preapproval context. For improved consis-
tency across trials, a guidance is being developed which identifies a standard core
item set to be considered for use across all oncology CER studies.
EV2
PAYERS AND PROS: BEYOND QOL
Miller KL, Stevens CA
PAREXEL Consulting, Waltham, MA, USA
At the 2010 ISPOR conference medical directors from US health and pharmacy
plans provided their perspective on the value of health outcomes research in de-
ciding drug coverage. The message to the ISPOR members was that quality of life
holds little sway among these decision-makers. Nevertheless health care research-
ers, policy makers, legislators, and other stakeholders continue to emphasize the
inclusion of the patient perspective in comparative effectiveness research (CER)
and in health care decision making. Recently, in arguing the importance of patient
reported outcomes (PROs) in CER, Wu, et al. emphasize that interventions must
“improv[e] outcomes, reduc[e] costs, or both”. Indeed, as these authors state “many
relevant outcomes require patient-reported information”. So if QOL measures
aren’t the answer, which PROs will provide both the patient perspective and infor-
mation critical to decision makers in the private and public sectors? Collaboration
between payers and researchers will be essential to answer this question. How-
ever, the onus will fall squarely upon the health outcomes researchers, to identify
and quantify the relationship between outcomes and value. Furthermore, these
researchers will have to demonstrate the importance to the individual payers, as
they have little incentive to further complicate drug coverage decision making.
Therefore, even if improved outcomes - as measured by PROs - prove to provide
meaningful benefit to patients, payers will require that the information be appli-
cable specifically to their populations. For instance Wu, et al. suggest functional
status 90 days after discharge as an example of a relevant patient outcome. We, as
health outcomes researchers understand the relevance to patients; but for payers
we must answer how is improved functional status a valuable measure to individ-
ual payers?Without the answer to this type of question, payers will be reluctant to
include these outcomes endpoints in their decision making.
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OBJECTIVES: Present a framework to systematically measure and combine key
attributes of health interventions into a single Comparative Effectiveness Index
(CEI).METHODS: Relevant attributes including efficacy/effectiveness, compliance/
persistency, safety, health-related quality of life (HRQoL)/utility are linked through
a transparent formula. Efficacy and effectiveness are gathered from a meta-anal-
ysis of randomized controlled trials and observational studies, accordingly. Com-
pliance and persistency are be derived from pharmacy claims data using metrics
such as the medication possession ratio. We propose a 5-point rating scale for the
safety measure from low risk “suitable for widespread use” to high risk “careful
consideration of risk versus benefit”. We also consider a combined measure of
risk-benefit assessment borrowing from existing quantitative methods such as a
Number Needed to Treat and Number Needed to Harm. Generic or disease-specific
patient-reported outcome measures provide information on the impact of the in-
tervention on the patient’s HRQoL and indicate the value of a specific treatment for
a given health state. To ensure relevant comparisons, we account for therapeutic
areawhen assessing the CEI ofmultiple interventions. Finally, ameasure of quality
of evidence (Jadad score) ensure that only evidence from robust designs fed the CEI.
CONCLUSION: The CEI aims to provide a comprehensive and balanced picture of
disparate yet linked performance attributes. Currently, a complete picture of
health interventions is not centralized and not easily accessible thus limiting in-
formed clinical decision-making by various stakeholders (physicians, patients,
payers and policy makers). This index is intended to guide healthcare participants
in making evidence-based clinical decisions at the population and patient levels
such that a providermight want to trade-off effectiveness for increase safety when
treating a patient with severe comorbidities. For full transparency and use, we
propose the creation of a US publically available web-based database of the infor-
mation underlying the index.
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MORE BANG FOR YOUR BUCK: TAKE A RISK WHEN ANALYSING INTERVIEW
DATA
Roberts G
Double Helix Consulting, London, UK
ISSUE: Data obtained by interview or questionnaire are routinely reported with
summary statistics, frequency, mean and range. Can we obtain more informative
results by interpreting the data using risk analysis techniques? OVERVIEW: Prob-
abilisticmethods can beusedwhendata is sparse and address areas of uncertainty.
Quantitative analysis of interview or questionnaire data typically involves present-
ing frequencies of response and summaries of aggregate data with descriptive
statistics. These are used often to address research questions including assessing
market access opportunities, pricing and reimbursement scenarios, filling gaps in
health economic data such as resource use. But dowe always get themost from the
data we have? How can we make better informed decisions? Let us consider a
hypothetical questionwhere respondents are asked to rate a series of attributes (A,
B, C) using a scale of 1 to 10. We end up with a distribution of answers that are
summarised as averages for each attribute. Oftenwe are then facedwith interpret-
ing a series of average scores that do not differ markedly between attributes. Un-
certainty in the ratings provided by respondents can be used to improve our inter-
pretation. One method would be to use bootstrap techniques, to sample with
replacement the raw data, and running a simulation to obtain the bootstrap un-
certainty distribution for the mean. From this we can determine the probability
that attribute A is better or worse than B or C.With this information at our disposal
we are better positioned to make an informed decision. CONCLUSION: Decision
analytic methods add value, improve communication about risk, support decision
making, and identify research opportunities for reducing uncertainty when inter-
preting interview and questionnaire data.
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USING COST-EFFECTIVENESS INFORMATION TO ALLOCATE MEDICARE
RESOURCES – HOW MUCH MORE HEALTH FOR THE MONEY?
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OBJECTIVES: The Centers for Medicare and Medicaid Services (CMS) do not explic-
itly use cost-effectiveness information in national coverage determinations
(NCDs). The objective of this studywas to estimate potential gains in health attain-
able from reallocating resources using cost-effectiveness information within the
existing level of spending, and to determine the consequences for the distribution
of resources.METHODS:NCDs from 1999 through 2007were included. Estimates of
the cost-effectiveness of included coverage decisions, both positive and non-cov-
erage, were identified from a literature review. For coverage decisions with an
associated estimate of cost-effectiveness (n66), an estimate of utilization and size
of the ‘unserved’ eligible patient population was established from a Medicare 5%
claims database (2007) using a combination of diagnostic (ICD-9) and reimburse-
ment (CPT) codes. Annual and net costs were taken from the cost-effectiveness
study or estimated using reimbursement codes. RESULTS: Complete information
was available for 36 (55%) coverage decisions with an associated estimate of cost-
effectiveness. A reallocation of resources yielded an increase in aggregate quality
adjusted life years (QALYs) of 1.8 million, approximately 0.15 QALYs per Medicare
beneficiary affected by the reallocation. The analysis provides a quantification of
how the reallocation affected different patient populations and the utilization of
different types of technology. In summary, following reallocation, a greater pro-
portion of resources were directed to oncology, diagnostic imaging and tests, and
diseases affecting 1 million Medicare beneficiaries, than prior to reallocation.
Conversely, following reallocation, a decreased proportion of resources were di-
rected to cardiology, interventions other than diagnostic tests, and diseases affect-
ing 50k-1millionMedicare beneficiaries, than prior to reallocation.CONCLUSIONS:
Using cost-effectiveness information to inform CMS NCDs has the potential to sub-
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